SRR1391639
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TNFA_SIGNALING_VIA_NFKB+0.383
- XENOBIOTIC_METABOLISM+0.318
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.312
- KRAS_SIGNALING_DN+0.304
- APOPTOSIS+0.295
- INFLAMMATORY_RESPONSE+0.293
- COAGULATION+0.292
- MYOGENESIS+0.291
- FATTY_ACID_METABOLISM+0.289
- BILE_ACID_METABOLISM+0.280
Top 10 suppressed
- MYC_TARGETS_V1-0.468
- E2F_TARGETS-0.420
- G2M_CHECKPOINT-0.417
- DNA_REPAIR-0.399
- UNFOLDED_PROTEIN_RESPONSE-0.376
- PROTEIN_SECRETION-0.375
- MYC_TARGETS_V2-0.306
- PI3K_AKT_MTOR_SIGNALING-0.301
- MITOTIC_SPINDLE-0.287
- MTORC1_SIGNALING-0.253
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1341521 | GTEX | — | 0.938 |
| 2 | SRR1491293 | GTEX | — | 0.929 |
| 3 | SRR1381757 | GTEX | — | 0.910 |
| 4 | SRR1320180 | GTEX | — | 0.908 |
| 5 | SRR818057 | GTEX | — | 0.890 |
| 6 | SRR1337412 | GTEX | — | 0.889 |
| 7 | SRR1459211 | GTEX | — | 0.884 |
| 8 | SRR1443895 | GTEX | — | 0.881 |
| 9 | SRR1364739 | GTEX | — | 0.881 |
| 10 | SRR1338923 | GTEX | — | 0.880 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 34 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.383 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.318 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.312 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.304 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.295 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.293 | Idelalisib | — uncovered |
| COAGULATION | 0.292 | Binimetinib | — uncovered |
| MYOGENESIS | 0.291 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.289 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.280 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.270 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.259 | Idelalisib | — uncovered |
| HYPOXIA | 0.234 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.214 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.211 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.208 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.175 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.174 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.173 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.172 | Remibrutinib | — uncovered |